(Q24235770)

5

0 references

Katja Komossa

1

0 references

author name string

Anna M Depping

2

0 references

Magdalena Meyer

Cochrane Database of Systematic Reviews

3

0 references

publication date

8 December 2010

0 references

published in

0 references

cites work

Effects of quetiapine on cognitive functioning in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Paroxetine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Imputing missing standard deviations in meta-analyses can provide accurate results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

The Yale-Brown Obsessive Compulsive Scale. II. Validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Pharmacotherapy for anxiety disorders in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

The neural bases of obsessive-compulsive disorder in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

Treatment for mood and anxiety disorders: quetiapine and aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

7 January 2021

Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

7 January 2021

Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

7 January 2021

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

7 January 2021

A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

7 January 2021

Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008141.PUB2

7 January 2021

10.1002/14651858.CD008141.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_g4zdhcuaorccdm3sbrhkkv5cee

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/g4zdhcuaorccdm3sbrhkkv5cee

24 November 2022